Your browser doesn't support javascript.
loading
Insertional Mutagenesis Identifies a STAT3/Arid1b/ß-catenin Pathway Driving Neurofibroma Initiation.
Wu, Jianqiang; Keng, Vincent W; Patmore, Deanna M; Kendall, Jed J; Patel, Ami V; Jousma, Edwin; Jessen, Walter J; Choi, Kwangmin; Tschida, Barbara R; Silverstein, Kevin A T; Fan, Danhua; Schwartz, Eric B; Fuchs, James R; Zou, Yuanshu; Kim, Mi-Ok; Dombi, Eva; Levy, David E; Huang, Gang; Cancelas, Jose A; Stemmer-Rachamimov, Anat O; Spinner, Robert J; Largaespada, David A; Ratner, Nancy.
Affiliation
  • Wu J; Division of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital University of Cincinnati, Cincinnati, OH 45229, USA.
  • Keng VW; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA; Department of Pediatrics, Cell Biology and Development, University of Minnesota, Minneapolis, MN 55455, USA; Center for Genome Engineering, University of Minnesota, Minneapolis, MN 55455, USA.
  • Patmore DM; Division of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital University of Cincinnati, Cincinnati, OH 45229, USA.
  • Kendall JJ; Division of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital University of Cincinnati, Cincinnati, OH 45229, USA.
  • Patel AV; Division of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital University of Cincinnati, Cincinnati, OH 45229, USA.
  • Jousma E; Division of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital University of Cincinnati, Cincinnati, OH 45229, USA.
  • Jessen WJ; Division of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital University of Cincinnati, Cincinnati, OH 45229, USA.
  • Choi K; Division of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital University of Cincinnati, Cincinnati, OH 45229, USA.
  • Tschida BR; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA; Center for Genome Engineering, University of Minnesota, Minneapolis, MN 55455, USA.
  • Silverstein KA; Biostatistics and Informatics, University of Minnesota, Minneapolis, MN 55455, USA.
  • Fan D; Biostatistics and Informatics, University of Minnesota, Minneapolis, MN 55455, USA.
  • Schwartz EB; Ohio State University, College of Pharmacy, Columbus, OH 43210, USA.
  • Fuchs JR; Ohio State University, College of Pharmacy, Columbus, OH 43210, USA.
  • Zou Y; Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Research Foundation, Cincinnati Children's Hospital University of Cincinnati, Cincinnati, OH 45229, USA.
  • Kim MO; Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Research Foundation, Cincinnati Children's Hospital University of Cincinnati, Cincinnati, OH 45229, USA.
  • Dombi E; Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA.
  • Levy DE; Department of Pathology and New York University Cancer Institute, New York University School of Medicine, 550 First Avenue, New York, NY 10016, USA.
  • Huang G; Division of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital University of Cincinnati, Cincinnati, OH 45229, USA.
  • Cancelas JA; Division of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital University of Cincinnati, Cincinnati, OH 45229, USA; Hoxworth Blood Center, College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.
  • Stemmer-Rachamimov AO; Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA.
  • Spinner RJ; Department of Neurologic Surgery, Mayo Clinic, Rochester, MN 55905, USA.
  • Largaespada DA; Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA; Department of Pediatrics, Cell Biology and Development, University of Minnesota, Minneapolis, MN 55455, USA; Center for Genome Engineering, University of Minnesota, Minneapolis, MN 55455, USA.
  • Ratner N; Division of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital University of Cincinnati, Cincinnati, OH 45229, USA. Electronic address: nancy.ratner@cchmc.org.
Cell Rep ; 14(8): 1979-90, 2016 Mar 01.
Article in En | MEDLINE | ID: mdl-26904939
ABSTRACT
To identify genes and signaling pathways that initiate Neurofibromatosis type 1 (NF1) neurofibromas, we used unbiased insertional mutagenesis screening, mouse models, and molecular analyses. We mapped an Nf1-Stat3-Arid1b/ß-catenin pathway that becomes active in the context of Nf1 loss. Genetic deletion of Stat3 in Schwann cell progenitors (SCPs) and Schwann cells (SCs) prevents neurofibroma formation, decreasing SCP self-renewal and ß-catenin activity. ß-catenin expression rescues effects of Stat3 loss in SCPs. Importantly, P-STAT3 and ß-catenin expression correlate in human neurofibromas. Mechanistically, P-Stat3 represses Gsk3ß and the SWI/SNF gene Arid1b to increase ß-catenin. Knockdown of Arid1b or Gsk3ß in Stat3(fl/fl);Nf1(fl/fl);DhhCre SCPs rescues neurofibroma formation after in vivo transplantation. Stat3 represses Arid1b through histone modification in a Brg1-dependent manner, indicating that epigenetic modification plays a role in early tumorigenesis. Our data map a neural tumorigenesis pathway and support testing JAK/STAT and Wnt/ß-catenin pathway inhibitors in neurofibroma therapeutic trials.
Subject(s)
Carcinogenesis/genetics; DNA-Binding Proteins/genetics; Gene Expression Regulation, Neoplastic; N-Terminal Acetyltransferase A/genetics; Neurofibromatosis 1/genetics; Peripheral Nervous System Neoplasms/genetics; STAT3 Transcription Factor/genetics; beta Catenin/genetics; Animals; Carcinogenesis/metabolism; Carcinogenesis/pathology; DNA Helicases/genetics; DNA Helicases/metabolism; DNA-Binding Proteins/antagonists & inhibitors; DNA-Binding Proteins/metabolism; Disease Models, Animal; Female; Glycogen Synthase Kinase 3 beta/antagonists & inhibitors; Glycogen Synthase Kinase 3 beta/genetics; Glycogen Synthase Kinase 3 beta/metabolism; Histones/genetics; Histones/metabolism; Humans; Mice; Mice, Nude; Mutagenesis, Insertional; N-Terminal Acetyltransferase A/antagonists & inhibitors; N-Terminal Acetyltransferase A/metabolism; Neoplasm Transplantation; Neural Stem Cells/metabolism; Neural Stem Cells/pathology; Neurofibromatosis 1/metabolism; Neurofibromatosis 1/pathology; Neurofibromin 1/genetics; Neurofibromin 1/metabolism; Nuclear Proteins/genetics; Nuclear Proteins/metabolism; Peripheral Nervous System Neoplasms/metabolism; Peripheral Nervous System Neoplasms/pathology; Phosphorylation; RNA, Small Interfering/genetics; RNA, Small Interfering/metabolism; STAT3 Transcription Factor/antagonists & inhibitors; STAT3 Transcription Factor/metabolism; Schwann Cells/metabolism; Schwann Cells/pathology; Signal Transduction; Transcription Factors/genetics; Transcription Factors/metabolism; beta Catenin/metabolism

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Peripheral Nervous System Neoplasms / Gene Expression Regulation, Neoplastic / Neurofibromatosis 1 / DNA-Binding Proteins / STAT3 Transcription Factor / Beta Catenin / N-Terminal Acetyltransferase A / Carcinogenesis Type of study: Prognostic_studies Language: En Journal: Cell Rep Year: 2016 Document type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Peripheral Nervous System Neoplasms / Gene Expression Regulation, Neoplastic / Neurofibromatosis 1 / DNA-Binding Proteins / STAT3 Transcription Factor / Beta Catenin / N-Terminal Acetyltransferase A / Carcinogenesis Type of study: Prognostic_studies Language: En Journal: Cell Rep Year: 2016 Document type: Article Affiliation country: United States
...